A Comparative Study of Liver Steatosis in Lean and Obese Patients with Non-alcoholic Fatty Liver Disease Based on Bioelectrical Impedance Analysis and Controlled Attenuation Parameter
Published: 2023-07-06
Page: 51-71
Issue: 2023 - Volume 5 [Issue 1]
Ahmed El-Shamy
Tropical Medicine and Infectious Diseases Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Abdelrahman Kobtan
Tropical Medicine and Infectious Diseases Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Gamal Kasem
Tropical Medicine and Infectious Diseases Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Rehab Badawi
Tropical Medicine and Infectious Diseases Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
*Author to whom correspondence should be addressed.
Abstract
Background: Due to the predominance of obesity, bad eating habits, and sedentary lifestyle patterns, non-alcoholic fatty liver disease (NAFLD) is becoming an international health issue and accounts for 25% of prevalence globally. Although there was evidence that the pathophysiology of NAFLD was mostly influenced by increasing body fat, particularly abdominal visceral fat, recent epidemiological studies have reported an increase of non-obese individuals who have NAFLD worldwide. In order to evaluate the degree of steatosis and identify the metabolic profiles of lean NAFLD patients, this study evaluated the liver fatty liver disease and body composition of obese and lean NAFLD patients.
Methods: In this cross-sectional research, a hundred individuals participated aged more than 18 years old, both sexes, with clinical criteria of bright liver by ultrasound then NAFLD diagnosed by Controlled Attenuation Parameter (CAP) determination of liver steatosis more than 240 dB/min. Patients were divided into two categories: 50 individuals with hepatic steatosis made up Group 1 (the study group), which was further split into: 1a: Count 25 individuals that are fatty or overweight (BMI 25 kg/m2), and 1b: Include 25 people who are not obese (BMI <25 kg/m2). Group 2 (control group): included 50 participants without liver steatosis, further subdivided into: 2a: include 25 overweight-obese participants (BMI≥25kg/m2) and 2b: include 25 non obese participants (BMI<25kg/m2).
Results: The proportion of body fat, visceral fat, subcutaneous fat, free-fat mass index (FFMI), and fat mass index (FMI) in the NAFLD group elevated substantially more than those in the non-NAFLD group (P <0.001). The steatosis score and the systolic, diastolic, and triglyceride (TG) levels were positively correlated in the obese NAFLD group (P=0.039, =0.002, and =0.012, respectively). The risk variables for NAFLD in lean individuals were elevated TG, reduced lymphocytes, increased neutrophil-to-lymphocyte ratio (NLR), increased Homeostatic model assessment (HOMA), and decreased FFMI.
Conclusions: While raised systolic blood pressure and elevated triglycerides were the only independent risk factors for the development of NAFLD in obese individuals, increasing visceral obesity and insulin resistance, HOMA IR were the only independent risk factor for the development of NAFLD in lean patients.
Keywords: NAFLD, lean NAFLD, body composition analysis
How to Cite
Downloads
References
Yi M, Chen RP, Yang R, Chen H. Increased prevalence and risk of non-alcoholic fatty liver disease in overweight and obese patients with type 2 diabetes in South China. Diabet Med. 2017; 34:505-13.
Zelber-Sagi S, Shoham D, Zvibel I, Abu-Abeid S, Shibolet O, Fishman S. Predictors for advanced fibrosis in morbidly obese non-alcoholic fatty liver patients. World J Hepatol. 2017; 9:91-8.
Arrese M. Nonalcoholic fatty liver disease: liver disease: an overlooked complication of diabetes mellitus. Nat Rev Endocrinol. 2010; 6:660-1.
Boursier J, Vergniol J, Guillet A, Hiriart JB, Lannes A, Le Bail B, et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J Hepatol. 2016; 65:570-8.
Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: Analysis of clinical background. J Gastroenterol. 2003; 38:954-61.
Riquelme A, Arrese M, Soza A, Morales A, Baudrand R, Pérez-Ayuso RM, et al. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int. 2009;29:82-8.
WHO. Physical status: The use and interpretation of anthropometry. Report on a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995; 854:1-452.
Cova I, Pomati S, Maggiore L, Forcella M, Cucumo V, Ghiretti R, et al. Nutritional status and body composition by bioelectrical impedance vector analysis: A cross sectional study in mild cognitive impairment and Alzheimer's disease. PLoS One. 2017; 12:13-31.
Siddiqui MS, Vuppalanchi R, Van Natta ML, Hallinan E, Kowdley KV, Abdelmalek M. NASH Clinical Research Network. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology. 2019;17(1):156-163.
Zelber-Sagi S, Shoham D, Zvibel I, Abu-Abeid S, Shibolet O, Fishman S. Predictors for advanced fibrosis in morbidly obese non-alcoholic fatty liver patients. World J Hepatol. 2017; 9:91-8.
Hartz AJ, Rupley DC, Rimm AA. The association of girth measurements with disease in 32,856 women. Am J Epidemiol. 1984;119:71-80.
Jaeschke H. Reactive oxygen and mechanisms of inflammatory liver injury: Present concepts. J Gastroenterol Hepatol. 2011;26:173-9.
Uribe-Querol E, Rosales C. Neutrophils Actively Contribute to Obesity-Associated Inflammation and Pathological Complications. Cells. 2022;11(12):1883.
Paquissi FC. Immune imbalances in non-alcoholic fatty liver disease: From general biomarkers and neutrophils to interleukin-17 axis activation and new therapeutic targets. Front Immunol. 2016;7:490.
DeFilippis AP, Blaha MJ, Martin SS, Reed RM, Jones SR, Nasir K, Budoff MJ. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2013;227(2): 429-436.
Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 2013; 48:434-41.
Nestel PJ, Schreibman PH, Ahrens EH, Jr. Cholesterol metabolism in human obesity. J Clin Invest. 1973;52:2389-97.
Malhotra P, Gill RK, Saksena S, Alrefai WA. Disturbances in cholesterol homeostasis and non-alcoholic fatty liver diseases. Front Med (Lausanne). 2020; 7:467.
Fon Tacer K, Rozman D. Nonalcoholic fatty liver disease: Focus on lipoprotein and lipid deregulation. J Lipids. 2011; 2011:78-9.
Yoo HJ, Park MS, Lee CH, Yang SJ, Kim TN, Lim KI, et al. Cutoff points of abdominal obesity indices in screening for non-alcoholic fatty liver disease in Asians. Liver Int. 2010; 30:1189-96.
Houghton D, Zalewsk, P, Hallsworth K, Cassidy S, Thoma C Avery L, Trenell M I. The degree of hepatic steatosis is associated with impaired cardiac and autonomic function. Journal of hepatology. 2019;70(6):1203-1213.
Donini LM, Busetto L, Bischoff SC, Cederholm T, Ballesteros-Pomar MD, Batsis JA, et al. Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement. Obes Facts. 2022; 15:321-35.
Yodoshi T, Orkin S, Arce Clachar AC, Bramlage K, Sun Q, Fei L, et al. Muscle mass is linked to liver disease severity in pediatric nonalcoholic fatty liver disease. J Pediatr. 2020; 223:93-9.
Zhai Y, Xiao Q. The common mechanisms of sarcopenia and NAFLD. BioMed Research International; 2017.
Garjani A, Safaeiyan A, Khoshbaten M. Association between platelet count as a noninvasive marker and ultrasonographic grading in patients with nonalcoholic Fatty liver disease. Hepat Mon. 2015;15:4-9.
López-Trujillo MA, Olivares-Gazca JM, Cantero-Fortiz Y, García-Navarrete YI, Cruz-Mora A, Olivares-Gazca JC, et al. Nonalcoholic fatty liver disease and thrombocytopenia III: Its association with insulin resistance. Clin Appl Thromb Hemost. 2019; 25:10-7.
Rivera-Álvarez M, Córdova-Ramírez AC, Elías-De-La-Cruz GD, Murrieta-Álvarez I, León-Peña AA, Cantero-Fortiz Y, Ruiz-Argüelles GJ. Non-alcoholic fatty liver disease and thrombocytopenia IV: Its association with granulocytopenia. Hematology, Transfusion and Cell Therapy. 2022;44: 491-496.
Cameron AJ, Magliano DJ, Shaw JE, Zimmet PZ, Carstensen B, Alberti KG, et al. The influence of hip circumference on the relationship between abdominal obesity and mortality. Int. J Epidemiol. 2012; 41:484-94.
López-Amador N, Nolasco-Hipolito C, Rojas-Jimeno M, Carvajal-Zarrabal O. Liver enzymes in patients diagnosed with non-alcoholic fatty liver disease (NAFLD) in Veracruz: A comparative analysis with the literature. Clinical Investigation. 2017; 7:25-32.
Vinodhini VM, Sudhan KB. Gamma-glutamyl transferase as an indicator of obesity: A cross-sectional study. Asian J Pharm Clin Res. 2016; 9(Suppl 3): 240-242.
DeFilippis AP, Blaha MJ, Martin SS, Reed RM, Jones SR, Nasir K, et al. Nonalcoholic fatty liver disease and serum lipoproteins: The multi-ethnic study of atherosclerosis. Atherosclerosis. 2013; 227:429-36.
Tominaga K, Fujimoto E, Suzuki K, Hayashi M, Ichikawa M, Inaba Y. Prevalence of non-alcoholic fatty liver disease in children and relationship to metabolic syndrome, insulin resistance, and waist circumference. Environ Health Prev Med. 2009; 14:142-9.
Ko YH, Wong TC, Hsu YY, Kuo KL, Yang SH. The Correlation Between Body Fat, Visceral Fat, and Nonalcoholic Fatty Liver Disease. Metab Syndr Relat Disord. 2017;15:304-11.
Dai H, Xiang J, Hou Y, Xuan L, Wang T, Li M, et al. Fat mass to fat-free mass ratio and the risk of non-alcoholic fatty liver disease and fibrosis in non-obese and obese individuals. Nutr Metab (Lond). 2021;18:21.
Ranasinghe C, Gamage P, Katulanda P, Andraweera N, Thilakarathne S, Tharanga P. Relationship between Body Mass Index (BMI) and body fat percentage, estimated by bioelectrical impedance, in a group of Sri Lankan adults: A cross sectional study. BMC Public Health. 2013;13:797.
Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment Pharmacol Ther. 2017; 46:85-95.
Wang W, Ren J, Zhou W, Huang J, Wu G, Yang F, et al. Lean non-alcoholic fatty liver disease (Lean-NAFLD) and the development of metabolic syndrome: a retrospective study. Sci Rep. 2022;12:10-77.
Zhang NP, Liu XJ, Xie L, Shen XZ, Wu J. Impaired mitophagy triggers NLRP3 inflammasome activation during the progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis. Lab Invest. 2019;99:749-63.